First discovered in 1989, hepatitis C virus (HCV) is a leading cause of chronic liver disease, hepatocellular carcinoma and liver failure worldwide. The prevalence of advanced liver disease attributed to chronic HCV infection is projected to rise and efforts to identify treatment candidates will have a greater impact as more effective antiviral therapy becomes available. In the eight chapters of this book, international experts explore the emergent drug classes and specific agents offering hope in HCV therapy and highlight future directions for research in addressing this serious and widespread problem.
